Trial · NCT04426578
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Left Ventricular Hypertrophy (LVH) | 12 months post baseline | Change in LVH (septal thickness) in symptomatic at 12 months following perhexiline therapy in HCM patients assessed by CMR |
| Secondary | Change in Left Ventricular (LV) mass | 12 months post baseline | Change in left ventricular mass in symptomatic at 12 months following perhexiline therapy in HCM patients assessed by CMR |
| Secondary | Change in oxygen-sensitive Cardiac Magnetic Resonance | 12 months post baseline | Change in oxygen-sensitive CMR in symptomatic at 12 months following perhexiline therapy in HCM patients |
| Secondary | Change in left ventricular diastolic function | 12 months post baseline | Change in left ventricular diastolic function at 12 months following perhexiline therapy in HCM patients assessed by echocardiography |
| Secondary | New York Heart Association (NYHA) functional classification | 12 months post baseline | Change in NYHA classification of Class I, II, III and IV at 12 months following perhexiline therapy in HCM patients |
| Secondary | Canadian Cardiovascular Society (CCS) functional class | 12 months post baseline | Change in CCS functional classification of Grade I, II, III and IV at 12 months following perhexiline therapy in HCM patients |
| Secondary | Quality of life assessment | 12 months post baseline | Change in physical activity domain score of Short Form 36 Health Survey Questionnaire (SF36) at 12 months following perhexiline therapy in HCM patients |
| Secondary | Major adverse event on heart failure related hospitalisations | Monitored over the 12 months period | HCM patients admitted with heart failure during the study period |
| Secondary | Major adverse event on arrhythmic events | Monitored over the 12 months period | HCM patients admitted with arrhythmic events during the study period |
| Secondary | Major adverse event on abnormal liver function test | Liver function tests at baseline, 1 month, 6 months and 12 months | HCM patients with abnormal liver function tests during the study period |
| Secondary | Major adverse event on sudden cardiac death | Monitored over the 12 months period | HCM patients with sudden cardiac death during the study period |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04426578/registered